US6770283B1
(en)
*
|
1990-12-13 |
2004-08-03 |
Bioption Ab |
DNA expression systems based on alphaviruses
|
US6015686A
(en)
*
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
EP0711829A3
(en)
|
1993-09-15 |
1997-07-09 |
Viagene Inc |
Recombinant alphavirus vector
|
SE9401091D0
(sv)
*
|
1994-03-31 |
1994-03-31 |
Bioption Ab |
Alphavirus cDNA vectors
|
SE9401709D0
(sv)
*
|
1994-05-18 |
1994-05-18 |
Mathilda Sjoeberg |
Improved alphavirus vectors for expression of heterologous DNA
|
US5505947A
(en)
*
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
DE19512142A1
(de)
*
|
1995-03-31 |
1996-10-02 |
Immuno Ag |
Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
|
US5639650A
(en)
*
|
1995-05-23 |
1997-06-17 |
The University Of North Carolina At Chapel Hill |
cDNA clone for South African Arbovirus No. 86
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US6465634B1
(en)
|
1996-04-05 |
2002-10-15 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
US6451592B1
(en)
*
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
US5939262A
(en)
*
|
1996-07-03 |
1999-08-17 |
Ambion, Inc. |
Ribonuclease resistant RNA preparation and utilization
|
US5677124A
(en)
*
|
1996-07-03 |
1997-10-14 |
Ambion, Inc. |
Ribonuclease resistant viral RNA standards
|
WO1998013511A1
(en)
*
|
1996-09-25 |
1998-04-02 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
|
CA2268353A1
(en)
*
|
1996-10-10 |
1998-04-16 |
Henrik Garoff |
Alphavirus-retrovirus vectors
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US5811407A
(en)
*
|
1997-02-19 |
1998-09-22 |
The University Of North Carolina At Chapel Hill |
System for the in vivo delivery and expression of heterologous genes in the bone marrow
|
US6432699B1
(en)
*
|
1997-03-28 |
2002-08-13 |
New York University |
Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
|
EP2386630A1
(en)
|
1997-10-14 |
2011-11-16 |
Darwin Molecular Corporation |
Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
|
EP1900818A3
(en)
|
1997-11-06 |
2008-06-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisserial antigens
|
CA2309826A1
(en)
|
1997-11-14 |
1999-05-27 |
Connaught Laboratories Limited |
Alphavirus vectors for paramyxovirus vaccines
|
CA2317815A1
(en)
|
1998-01-14 |
1999-07-22 |
Chiron S.P.A. |
Neisseria meningitidis antigens
|
US6844188B1
(en)
|
1998-04-08 |
2005-01-18 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
ATE457176T1
(de)
|
1998-04-08 |
2010-02-15 |
Univ North Carolina |
Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
|
EP2261343A3
(en)
|
1998-05-01 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Neisseria meningitidis antigens and compositions
|
EP1075523B1
(en)
*
|
1998-05-08 |
2007-08-08 |
Intervet International BV |
Structural proteins of fish pancreatic disease virus and uses thereof
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
MXPA01005389A
(es)
*
|
1998-11-30 |
2003-03-27 |
Cytos Biotechnology Ag |
Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
|
EP1141331B1
(en)
|
1998-12-16 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
|
US8647864B2
(en)
*
|
1999-04-14 |
2014-02-11 |
Novartis Ag |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
JP4637368B2
(ja)
*
|
1999-04-14 |
2011-02-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
|
DK1228217T3
(da)
|
1999-04-30 |
2013-02-25 |
Novartis Vaccines & Diagnostic |
Konserverede neisseria-antigener
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6297013B1
(en)
|
1999-06-24 |
2001-10-02 |
Dnab Diagnostics Inc. |
Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
WO2001030847A1
(en)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
CA2387921A1
(en)
|
1999-10-26 |
2001-05-03 |
International Aids Vaccine Initiative |
Invasive bacterial vectors for expressing alphavirus replicons
|
ES2543736T3
(es)
|
1999-10-29 |
2015-08-21 |
Glaxosmithkline Biologicals Sa |
Péptidos antigénicos de Neisseria
|
JP2003516731A
(ja)
|
1999-11-18 |
2003-05-20 |
カイロン コーポレイション |
ヒトfgf−21遺伝子および遺伝子発現産物
|
DK2289545T3
(en)
|
2000-01-17 |
2016-09-05 |
Glaxosmithkline Biologicals Sa |
Supplemented OMV vaccine against meningococcus
|
AU2001249125A1
(en)
|
2000-03-08 |
2001-09-17 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
WO2001085208A2
(en)
|
2000-05-05 |
2001-11-15 |
Cytos Biotechnology Ag |
Molecular antigen arrays and vaccines
|
ES2276788T3
(es)
|
2000-05-10 |
2007-07-01 |
Sanofi Pasteur Limited |
Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
|
ES2312447T3
(es)
|
2000-05-31 |
2009-03-01 |
Novartis Vaccines And Diagnostics, Inc. |
Procedimiento para la purificacion de particulas de replicon alfavirus.
|
US6783939B2
(en)
|
2000-07-07 |
2004-08-31 |
Alphavax, Inc. |
Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
|
WO2002020721A2
(en)
|
2000-09-07 |
2002-03-14 |
University Of North Carolina At Chapel Hill |
Vectors derived from south african arbovirus no. 86
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
EP2105496B1
(en)
|
2000-12-08 |
2013-02-20 |
Life Technologies Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US7128911B2
(en)
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
US7320793B2
(en)
*
|
2001-01-19 |
2008-01-22 |
Cytos Biotechnology Ag |
Molecular antigen array
|
US7094409B2
(en)
*
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
CA2440890C
(en)
*
|
2001-03-27 |
2011-07-19 |
New York University |
Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
EP1604688B1
(de)
|
2001-06-05 |
2010-02-03 |
CureVac GmbH |
Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
|
AU2002327614B2
(en)
|
2001-09-06 |
2007-12-06 |
Alphavax, Inc. |
Alphavirus replicon vector systems
|
US7115266B2
(en)
*
|
2001-10-05 |
2006-10-03 |
Cytos Biotechnology Ag |
Angiotensin peptide-carrier conjugates and uses thereof
|
BR0213117A
(pt)
|
2001-10-05 |
2004-09-21 |
Cytos Biotechnology Ag |
Conjugados peptìdeo angiotensina-veìculo e seus usos
|
DE60228758D1
(de)
|
2001-12-12 |
2008-10-16 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia tracheomatis
|
US7877273B2
(en)
*
|
2002-01-08 |
2011-01-25 |
Fredric David Abramson |
System and method for evaluating and providing nutrigenomic data, information and advice
|
US20030219459A1
(en)
*
|
2002-01-18 |
2003-11-27 |
Cytos Biotechnology Ag |
Prion protein carrier-conjugates
|
WO2003078453A1
(en)
|
2002-03-15 |
2003-09-25 |
Wyeth Holdings Corporation |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
ATE517122T1
(de)
|
2002-04-09 |
2011-08-15 |
Sanofi Pasteur Ltd |
Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
|
AU2004280608B2
(en)
*
|
2002-04-09 |
2012-04-05 |
Sanofi Pasteur, Inc. |
Modified CEA/B7 vector
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
JP4598519B2
(ja)
*
|
2002-06-20 |
2010-12-15 |
サイトス バイオテクノロジー アーゲー |
アジュバントとして使用するためのパッケージ化されたウィルス様粒子:調製法及び使用法
|
CN102061288A
(zh)
|
2002-07-17 |
2011-05-18 |
希托斯生物技术股份公司 |
使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
|
BR0312297A
(pt)
*
|
2002-07-18 |
2005-04-12 |
Cytos Biotechnology Ag |
Conjugados veìculos de hapteno e seu uso
|
SI1524994T1
(sl)
|
2002-07-19 |
2011-08-31 |
Cytos Biotechnology Ag |
Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
|
AU2003284239B2
(en)
|
2002-10-21 |
2008-08-21 |
Eisai Inc. |
Compositions and methods for treating human papillomavirus-mediated disease
|
DE60332477D1
(de)
|
2002-11-15 |
2010-06-17 |
Novartis Vaccines & Diagnostic |
Unerwartete oberflächenproteine in neisseria meningitidis
|
BRPI0317276B8
(pt)
|
2002-12-13 |
2021-05-25 |
Alphavax Inc |
método para a preparação de partículas de replicon de alfavírus (arps)
|
WO2004055166A2
(en)
|
2002-12-13 |
2004-07-01 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
WO2004063342A2
(en)
*
|
2003-01-09 |
2004-07-29 |
Invitrogen Corporation |
Cellular delivery and activation polypeptide-nucleic acid complexes
|
PL1608762T3
(pl)
|
2003-03-20 |
2014-06-30 |
Alphavax Inc |
Udoskonalone replikony alfawirusowe i konstrukty plazmidów pomocniczych
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1623229A2
(en)
*
|
2003-05-15 |
2006-02-08 |
Cytos Biotechnology AG |
Selection of b cells with specificity of interest: method of preparation and use
|
WO2005007689A1
(en)
|
2003-07-11 |
2005-01-27 |
Alphavax, Inc. |
Alphavirus-based cytomegalovirus vaccines
|
US7910093B2
(en)
|
2003-08-19 |
2011-03-22 |
New York University |
Method for detecting cancer cells and monitoring cancer therapy
|
CA2553594A1
(en)
*
|
2004-01-20 |
2005-07-28 |
Cytos Biotechnology Ag |
Particle-induced ghrelin immune response
|
KR101222281B1
(ko)
|
2004-03-29 |
2013-01-28 |
가르파마 컴퍼니 리미티드 |
신규 갈렉틴 9 개변체 단백질 및 그 용도
|
MXPA06013124A
(es)
|
2004-05-18 |
2007-05-23 |
Alphavax Inc |
Vectores de alfavirus derivados de tc-83, particulas y metodos.
|
ES2292271B1
(es)
*
|
2004-05-20 |
2009-02-16 |
Proyecto De Biomedicina Cima, S.L. |
Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
|
AU2005249218A1
(en)
*
|
2004-06-02 |
2005-12-15 |
Cytos Biotechnology Ag |
Medical uses of carrier conjugates of non-human TNF-peptides
|
US7189540B2
(en)
*
|
2004-06-21 |
2007-03-13 |
Quattromed As |
Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proteins
|
CA2572921C
(en)
|
2004-07-09 |
2017-01-03 |
The University Of North Carolina At Chapel Hill |
Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
WO2007046839A2
(en)
|
2005-02-15 |
2007-04-26 |
University Of North Carolina At Chapel Hill |
New live virus vaccines
|
EP3312196B1
(en)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
US7303898B2
(en)
*
|
2005-03-29 |
2007-12-04 |
New York University |
Defective sindbis viral vectors
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
US20090022760A1
(en)
|
2006-09-12 |
2009-01-22 |
Alphavax |
Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
|
EP2066346B1
(en)
|
2006-09-12 |
2019-07-03 |
AlphaVax, Inc. |
Alphavirus replicon particles encoding il-12 as immunological adjuvants
|
ES2673823T3
(es)
*
|
2006-11-03 |
2018-06-25 |
Alphavax, Inc. |
Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
|
EP2139447A2
(en)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
AU2008266807B2
(en)
|
2007-06-21 |
2012-08-16 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
PL2222697T3
(pl)
|
2007-11-01 |
2013-05-31 |
Astellas Pharma Inc |
Immunosupresyjne polipeptydy i kwasy nukleinowe
|
ES2525707T3
(es)
|
2008-12-01 |
2014-12-29 |
Alphavax, Inc. |
Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
|
AU2010234362B2
(en)
|
2009-04-08 |
2015-11-26 |
Alphavax, Inc. |
Alphavirus replicon particles expressing TRP2
|
US8563261B2
(en)
|
2009-09-28 |
2013-10-22 |
The Trustees Of The University Of Pennsylvania |
Method of diagnosing and treating interstitial cystitis
|
EE05711B1
(et)
|
2009-10-07 |
2014-04-15 |
Tartu Ülikool |
Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
|
WO2011064437A2
(es)
|
2009-11-26 |
2011-06-03 |
Proyecto De Biomedicina Cima, S.L. |
Vectores virales y procedimientos útiles en la preparación de gdnf
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
US9198975B2
(en)
|
2010-12-01 |
2015-12-01 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
WO2012101509A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi Pasteur Sa |
Immunological compositions against hiv
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US20190282679A1
(en)
*
|
2016-04-18 |
2019-09-19 |
Rima McLeod |
Toxoplasma gondii vaccines and their use
|
US10975369B2
(en)
*
|
2017-02-27 |
2021-04-13 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
US11926817B2
(en)
|
2019-08-09 |
2024-03-12 |
Nutcracker Therapeutics, Inc. |
Microfluidic apparatus and methods of use thereof
|